Im wondering why many if not all of your Amarin articles are generally negative on the company. You seem to downplay the potetial for vascepa but usually offer very little to substatiate your stance. Vascepa is superior to Lovaza, Im sure you understand that. The bottom of your articles state you are neither short or invested in the companies you write about. However, a real analyst covers the whole company, and is not one sided. I've never seen you write anything positive about it's growing patent portfolio, it's superior efficacy to Lovaza and of course, it's Anchor trial results, which have the potential to explode once approved. Can you explain why such a negative stance?
fyi, I've never bashed you on any message boards, afterall we're all entitled to our own opinions, Im just trying to understand yours.